HTR1A and attention deficit-hyperactivity disorder: PsychoGenics used SmartCube® to evaluate the efficacy of eltoprazine (a partial 5HT1A/1B agonist; this mechanism was not known to be effective for attention deficit hyperactivity disorder (ADHD)) in ADHD and proved its efficacy in humans by conducting a proof-of-concept study in patients with ADHD [34].